Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant’s fourth major strategic acquisition ...

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Detailed price information for Blueprint Medicines Corp (BPMC-Q) from The Globe and Mail including charting and trades.

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from ...

The stock, trading under the ticker (NASDAQ:BPMC), is a part of both the Nasdaq Biotechnology Index and the Nasdaq Today.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

VersaBank (VBNK.T) is expected to report $0.27 for 2Q. Powered by Onclusive and Dow Jones. Advance Auto Parts Raised to Neutral From Sell by Redburn Atlantic ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...